医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2015年
21期
67-67
,共1页
缩宫素%欣母沛%剖宫产%产后出血%疗效
縮宮素%訢母沛%剖宮產%產後齣血%療效
축궁소%흔모패%부궁산%산후출혈%료효
Oxytocin%Hemabate%Cesarean section%Postpartum hemor hage%Ef ect
目的:探讨静脉滴注缩宫素辅以宫体注射欣母沛在预防和治疗剖宫产术后出血的临床疗效。方法选择有剖宫产指征、具产后出血潜在因素的高危产妇160例按入:先后顺序,被随机分为观察和对照两组(n=80)。胎儿娩出后,在静脉滴注缩宫素的基础上,观察组辅以宫体注射欣母沛治疗,而对照组辅以宫体注射缩宫素治疗。比较组间产后出血的发生率以及术后2、24h的出血量。结果观察组产后出血发生率低于对照组;观察组产后2、24h的出血量均少于对照组,组间比较差异有统计学意义(<0.05)。结论静脉滴注缩宫素辅以宫体注射欣母沛用于防治产后出血,具有快速、安全的特点,值得推广。
目的:探討靜脈滴註縮宮素輔以宮體註射訢母沛在預防和治療剖宮產術後齣血的臨床療效。方法選擇有剖宮產指徵、具產後齣血潛在因素的高危產婦160例按入:先後順序,被隨機分為觀察和對照兩組(n=80)。胎兒娩齣後,在靜脈滴註縮宮素的基礎上,觀察組輔以宮體註射訢母沛治療,而對照組輔以宮體註射縮宮素治療。比較組間產後齣血的髮生率以及術後2、24h的齣血量。結果觀察組產後齣血髮生率低于對照組;觀察組產後2、24h的齣血量均少于對照組,組間比較差異有統計學意義(<0.05)。結論靜脈滴註縮宮素輔以宮體註射訢母沛用于防治產後齣血,具有快速、安全的特點,值得推廣。
목적:탐토정맥적주축궁소보이궁체주사흔모패재예방화치료부궁산술후출혈적림상료효。방법선택유부궁산지정、구산후출혈잠재인소적고위산부160례안입:선후순서,피수궤분위관찰화대조량조(n=80)。태인면출후,재정맥적주축궁소적기출상,관찰조보이궁체주사흔모패치료,이대조조보이궁체주사축궁소치료。비교조간산후출혈적발생솔이급술후2、24h적출혈량。결과관찰조산후출혈발생솔저우대조조;관찰조산후2、24h적출혈량균소우대조조,조간비교차이유통계학의의(<0.05)。결론정맥적주축궁소보이궁체주사흔모패용우방치산후출혈,구유쾌속、안전적특점,치득추엄。
Objective To explore the clinical ef icacy of Intravenous infusion of oxytocin combined with uterine body injected hemabate in the prevention and treatment of hemor hage after cesarean section.Methods According to the order of admission, 160 cases of high-risk mothers with indications for cesarean section, were randomly divided into observation and control group two (n=80). After delivery of fetus, in intravenous infusion of oxytocin on the contraction of the basis, the observation group with uterine body injected hemabate treatment, while the control group with injection of oxytocin treatment of uterine body. The incidence of postpartum hemorrhage were compared between and the amount of bleeding in the postoperative 2, 24 h.Results The observation group than in the control group the incidence of postpartum hemor hage, postpartum hemor hage; observation group of 2 volume of 24 h were less than that in the control group, there were statistical y significant dif erences between groups ( < 0.05).Conclusion Intravenous infusion of oxytocin combined with uterine body injected hemabate for prevention of postpartum hemor hage, with fast, safe, worthy of promotion.